Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics

Article Date
January 15, 2026

This article is featured on another website.

Go to article

Related posts

Browse all articles
February 10, 2026

Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.

February 10, 2026

Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.